|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
EP0052322B1
(de)
|
1980-11-10 |
1985-03-27 |
Gersonde, Klaus, Prof. Dr. |
Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
|
DE3218121A1
(de)
|
1982-05-14 |
1983-11-17 |
Leskovar, Peter, Dr.-Ing., 8000 München |
Arzneimittel zur tumorbehandlung
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
EP0143949B1
(en)
|
1983-11-01 |
1988-10-12 |
TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION |
Pharmaceutical composition containing urokinase
|
|
JPS62126123A
(ja)
|
1985-11-28 |
1987-06-08 |
Shigeki Suzuki |
バルプロ酸の経皮吸収方法
|
|
AU2514292A
(en)
|
1991-08-27 |
1993-03-16 |
Cygnus Therapeutic Systems |
Transdermal formulations for administering prazosin
|
|
US6032073A
(en)
|
1995-04-07 |
2000-02-29 |
Novartis Ag |
Iontophoretic transdermal system for the administration of at least two substances
|
|
US5736154A
(en)
*
|
1996-03-11 |
1998-04-07 |
Fuisz Technologies Ltd. |
Transdermal delivery system
|
|
FR2749514B1
(fr)
|
1996-06-11 |
1998-08-07 |
Hoechst Marion Roussel |
Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
|
|
US6479074B2
(en)
|
1996-10-24 |
2002-11-12 |
Pharmaceutical Applications Associates Llc |
Methods and transdermal compositions for pain relief
|
|
AU5495798A
(en)
|
1997-01-16 |
1998-08-07 |
Sekisui Chemical Co., Ltd. |
External preparations for percutaneous absorption
|
|
CN1331576A
(zh)
|
1998-06-29 |
2002-01-16 |
药品应用协会有限公司 |
用于缓解疼痛的方法和经皮组合物
|
|
JP2003503313A
(ja)
|
1999-06-03 |
2003-01-28 |
ジェシー エル エス オウ |
細胞増殖及び細胞死を変調する方法及び組成物
|
|
IL138686A0
(en)
|
1999-10-01 |
2001-10-31 |
Pfizer Prod Inc |
α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
|
|
EP1301619B1
(en)
|
2000-07-14 |
2006-10-18 |
Transform Pharmaceuticals, Inc. |
System and method for optimizing tissue barrier transfer of compounds
|
|
US6682757B1
(en)
*
|
2000-11-16 |
2004-01-27 |
Euro-Celtique, S.A. |
Titratable dosage transdermal delivery system
|
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
|
EP1293205A1
(en)
|
2001-09-18 |
2003-03-19 |
G2M Cancer Drugs AG |
Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
|
|
CA2466536C
(en)
|
2001-12-13 |
2012-02-07 |
Vital Health Sciences Pty Ltd |
Transdermal transport of compounds
|
|
US6841565B1
(en)
*
|
2002-03-29 |
2005-01-11 |
The Ohio State University |
Treatment of patients with chronic lymphocytic leukemia
|
|
EP1638963B1
(en)
|
2003-05-20 |
2009-09-09 |
Novartis AG |
N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
|
|
JP2009513523A
(ja)
|
2003-07-08 |
2009-04-02 |
ノバルティス アクチエンゲゼルシャフト |
ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物
|
|
US20050059682A1
(en)
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
|
US8012944B2
(en)
|
2003-10-30 |
2011-09-06 |
Pharmascience Inc. |
Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
|
|
AU2004293178B8
(en)
|
2003-11-26 |
2009-01-08 |
Novartis Ag |
Organic compounds
|
|
WO2005065668A2
(en)
|
2003-12-29 |
2005-07-21 |
Qlt Usa, Inc. |
Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
|
|
WO2005105009A1
(en)
|
2004-04-26 |
2005-11-10 |
Cassel Douglas R |
Wound treatment patch for alleviating pain
|
|
KR100602434B1
(ko)
|
2004-09-10 |
2006-07-19 |
최상식 |
복수 개의 단위 구획을 포함하는 약물의 경피 투여용 패치
|
|
US20080292616A1
(en)
|
2005-08-19 |
2008-11-27 |
Government Of The United Of America, Represented By The Secretary, Department Of Health And.... |
Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
WO2007041584A2
(en)
|
2005-10-03 |
2007-04-12 |
Combinatorx, Incorporated |
Implantable sensors, implantable pumps, and anti-scarring drug combinations
|
|
WO2007075077A1
(es)
|
2005-11-16 |
2007-07-05 |
Universidad Nacional Autonoma De Mexico |
Uso de agentes modificantes del transcriptoma más quimioterapia o radioterapia contra el cáncer
|
|
EP1971371B1
(en)
|
2005-12-01 |
2015-08-05 |
Pronai Therapeutics, Inc. |
Cancer therapies and pharmaceutical compositions used therein
|
|
US20110077215A1
(en)
|
2005-12-07 |
2011-03-31 |
The University Of Utah Research Foundation |
DNA Methylation As A Target For Diagnosis And Treatment Of Chronic Lymphocytic Leukema (CLL)
|
|
AU2006339445A1
(en)
|
2006-03-02 |
2007-09-07 |
Agency For Science, Technology And Research |
Methods for cancer therapy and stem cell modulation
|
|
US8585753B2
(en)
|
2006-03-04 |
2013-11-19 |
John James Scanlon |
Fibrillated biodegradable prosthesis
|
|
US8338416B2
(en)
*
|
2006-03-16 |
2012-12-25 |
Pharmacylics, Inc. |
Indole derivatives as inhibitors of histone deacetylase
|
|
EP2007370B1
(en)
|
2006-03-31 |
2013-12-18 |
Erasmus University Medical Center Rotterdam |
Novel composition for tumor growth control
|
|
US8076528B2
(en)
*
|
2006-05-05 |
2011-12-13 |
Coloplast A/S |
Pressure sensitive adhesive composition comprising cross-linked polyalkylene oxide and water absorbent hydrophilic agents
|
|
WO2008082646A2
(en)
|
2006-12-28 |
2008-07-10 |
The Johns Hopkins University |
Histone deacetylase inhibitors, combination therapies and methods of use
|
|
BRPI0807812A2
(pt)
|
2007-02-15 |
2020-06-23 |
Novartis Ag |
Combinações de lbh589 com outros agentes terapêuticos para tratar câncer
|
|
WO2008116163A1
(en)
|
2007-03-22 |
2008-09-25 |
Oregon Health & Science University |
Therapeutic drug combinations for treatment of b-cell malignancies
|
|
WO2008127735A1
(en)
|
2007-04-13 |
2008-10-23 |
Stemline Therapeutics, Inc. |
Il3ralpha antibody conjugates and uses thereof
|
|
US20090025274A1
(en)
|
2007-07-23 |
2009-01-29 |
Tim Lail |
Animal trap
|
|
RU2010120674A
(ru)
|
2007-10-22 |
2011-11-27 |
Шеринг Корпорейшн (US) |
Полностью человеческие анти-vegf-антитела и способы их применения
|
|
WO2009067453A1
(en)
*
|
2007-11-19 |
2009-05-28 |
Syndax Pharmaceuticals, Inc. |
Combinations of hdac inhibitors and proteasome inhibitors
|
|
US20110053991A1
(en)
*
|
2007-11-19 |
2011-03-03 |
Gore Lia |
Treatment of Histone Deacetylase Mediated Disorders
|
|
EP3782612B1
(en)
|
2008-05-15 |
2023-11-08 |
Celgene Corporation |
Oral formulations of cytidine analogs and methods of use thereof
|
|
WO2009155477A1
(en)
|
2008-06-19 |
2009-12-23 |
The Trustees Of The University Of Pennsylvania |
Inducible regulatory t-cell generation for hematopoietic transplants
|
|
WO2010020787A1
(en)
|
2008-08-22 |
2010-02-25 |
Oncomethylome Sciences Sa |
Diagnosis and treatment of tumours
|
|
SG176571A1
(en)
*
|
2009-05-19 |
2012-01-30 |
Vivia Biotech Sl |
Methods for providing personalized medicine tests ex vivo for hematological neoplasms
|
|
US8491927B2
(en)
*
|
2009-12-02 |
2013-07-23 |
Nimble Epitech, Llc |
Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
|
|
JP5548470B2
(ja)
*
|
2010-02-16 |
2014-07-16 |
日本碍子株式会社 |
ハニカム触媒体
|
|
US20110245154A1
(en)
*
|
2010-03-11 |
2011-10-06 |
Hemaquest Pharmaceuticals, Inc. |
Methods and Compositions for Treating Viral or Virally-Induced Conditions
|
|
EP2382993A1
(en)
*
|
2010-04-19 |
2011-11-02 |
KTB Tumorforschungsgesellschaft mbH |
Combination of drugs with protein-binding prodrugs
|
|
WO2012044936A1
(en)
*
|
2010-09-30 |
2012-04-05 |
Portola Pharmaceuticals, Inc. |
Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
|
|
ME02395B
(me)
*
|
2010-11-12 |
2016-09-20 |
Pharma Mar Sa |
Kombinovana terapija sa antitumorskim alkaloidima
|
|
US20130004481A1
(en)
*
|
2011-01-12 |
2013-01-03 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
|
US20140163026A1
(en)
*
|
2011-04-08 |
2014-06-12 |
Afraxis Holdings, Inc. |
8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of nervous system disorders and cancer
|
|
WO2012142480A1
(en)
*
|
2011-04-14 |
2012-10-18 |
Beth Israel Deaconess Medical Center, Inc. |
Chimeric rna oligonucleotides and uses thereof
|
|
US20140170148A1
(en)
*
|
2011-04-20 |
2014-06-19 |
Genmab A/S |
Bispecific antibodies against her2
|
|
EP2702173A1
(en)
*
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
CA2840413A1
(en)
*
|
2011-06-28 |
2013-01-03 |
Pharmacyclics, Inc. |
Methods and compositions for inhibition of bone resorption
|
|
US9125884B2
(en)
*
|
2011-11-01 |
2015-09-08 |
Celgene Corporation |
Methods for treating cancers using oral formulations of cytidine analogs
|
|
WO2013086451A2
(en)
*
|
2011-12-09 |
2013-06-13 |
Afraxis, Inc. |
Pak inhibitors for the treatment of cancer
|
|
JP2015518053A
(ja)
*
|
2012-05-31 |
2015-06-25 |
アムジエン・インコーポレーテツド |
癌の治療のためのａｍｇ９００の使用
|
|
JO3754B1
(ar)
*
|
2012-06-04 |
2021-01-31 |
Pharmacyclics Llc |
أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
|
|
WO2014009318A1
(en)
*
|
2012-07-11 |
2014-01-16 |
Boehringer Ingelheim International Gmbh |
3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
|
|
WO2014009319A1
(en)
*
|
2012-07-11 |
2014-01-16 |
Boehringer Ingelheim International Gmbh |
Indolinone derivatives anticancer compounds
|
|
DK2882737T3
(da)
*
|
2012-08-09 |
2019-05-13 |
Celgene Corp |
Fast form af (s)-3-(4-((4-morpholinmethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion hydrochlorid
|
|
BR112015002285B1
(pt)
*
|
2012-08-09 |
2022-05-10 |
Celgene Corporation |
Uso do composto 3-(4-((4-(morfolinometil)benzil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona para tratar ou gerenciar câncer
|
|
US9682143B2
(en)
*
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
AU2013302696B9
(en)
*
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US20140120083A1
(en)
*
|
2012-11-01 |
2014-05-01 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
|
SI2900277T1
(sl)
*
|
2012-12-13 |
2022-05-31 |
Immunomedics, Inc. |
Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
|